Hepion Pharmaceuticals Management
Management criteria checks 2/4
Hepion Pharmaceuticals' CEO is John Cavan, appointed in Mar 2016, has a tenure of 8.17 years. total yearly compensation is $495.33K, comprised of 77.4% salary and 22.6% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth €770.38. The average tenure of the management team and the board of directors is 6.4 years and 1.5 years respectively.
Key information
John Cavan
Chief executive officer
US$495.3k
Total compensation
| CEO salary percentage | 77.4% |
| CEO tenure | 8.2yrs |
| CEO ownership | 0.01% |
| Management average tenure | 6.4yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$39m |
| Dec 31 2023 | n/a | n/a | -US$49m |
| Sep 30 2023 | n/a | n/a | -US$48m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$495k | US$383k | -US$45m |
| Sep 30 2022 | n/a | n/a | -US$45m |
| Jun 30 2022 | n/a | n/a | -US$46m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$462k | US$350k | -US$33m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$25m |
| Mar 31 2021 | n/a | n/a | -US$22m |
| Dec 31 2020 | US$1m | US$325k | -US$20m |
| Sep 30 2020 | n/a | n/a | -US$18m |
| Jun 30 2020 | n/a | n/a | -US$13m |
| Mar 31 2020 | n/a | n/a | -US$15m |
| Dec 31 2019 | US$377k | US$291k | -US$12m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$20m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | US$339k | US$275k | -US$18m |
Compensation vs Market: John's total compensation ($USD495.33K) is about average for companies of similar size in the German market ($USD385.52K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Cavan (65 yo)
8.2yrs
Tenure
US$495,333
Compensation
Mr. John T. Cavan has been the Chief Financial Officer at Hepion Pharmaceuticals, Inc. (formerly known as ContraVir Pharmaceuticals, Inc.) since March 2016 and serves as its Interim CEO since December 7, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & CFO | 8.2yrs | US$495.33k | 0.014% $ 770.4 | |
| Director of Investor Relations | no data | no data | no data | |
| Part-Time Consultant | 6.4yrs | US$34.62k | no data | |
| Scientific Advisory Board Chair & Consultant Medical Director | 4.6yrs | no data | no data |
6.4yrs
Average Tenure
Experienced Management: 336's management team is seasoned and experienced (6.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Scientific Advisory Board Chair & Consultant Medical Director | 4.8yrs | no data | no data | |
| Independent Chairman | 11yrs | US$86.00k | 0.0064% $ 362.9 | |
| Independent Director | 10.5yrs | US$77.90k | no data | |
| Member of Scientific Advisory Board | 1.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
| Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 1.2yrs | no data | no data | |
| Independent Director | 1.9yrs | US$30.92k | no data |
1.5yrs
Average Tenure
67yo
Average Age
Experienced Board: 336's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.